Filter By Category
Archives
Share on -
AMLINTIDE
Generic Name: AMLINTIDE
ABSTRACT -
Amlintide is an amylin-based peptide related to human amylin biology. Amylin peptides influence satiety, gastric emptying, post-prandial glucagon secretion, and glucose homeostasis, but amlintide does not have a widely established routine therapeutic role in most markets. Because it is a peptide, a compact conventional small-molecule structural formula is not appropriate; the representation above shows a peptide-chain schematic.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No broadly approved standard dosing regimen is established for routine self-administration.
- Use only according to a validated label, compounding specification, or approved clinical protocol.
- Dose changes, if any, should consider glucose monitoring, gastrointestinal tolerability, and concomitant antidiabetic therapy.
SIDE EFFECTS–
- Possible side effects include:
- Nausea
- Vomiting
- Reduced appetite
- Abdominal discomfort
- Dizziness
- Headache
- Injection-site reactions if administered by injection
- Hypoglycaemia when used with insulin or insulin secretagogues
- Potential allergic reactions to peptide products
ALLRGIC REACTIONS–
- Hypersensitivity to amlintide, peptide excipients, or formulation components may occur.
- Symptoms may include rash, itching, urticaria, facial swelling, throat tightness, wheezing, or anaphylaxis.
- Important: Patients who develop an allergic reaction to Amlintide should seek immediate medical attention.
DRUG INTERACTIONS–
- Insulin and sulfonylureas may increase hypoglycaemia risk when combined with amylin-like therapies.
- Medicines requiring rapid gastrointestinal absorption may be affected if gastric emptying is slowed.
- Other glucose-lowering agents require careful monitoring and dose adjustment by a clinician.
- Alcohol may increase the risk of hypoglycaemia and dizziness.
PREAUTIONS–
- Use caution in patients with recurrent severe hypoglycaemia or impaired hypoglycaemia awareness.
- Use caution in significant gastrointestinal motility disorders.
- Safety in pregnancy, lactation, and children is not established unless covered by a specific label.
- Monitor blood glucose closely when used with diabetes medicines.
WARNINGS –
- Do not use without professional supervision.
- Hypoglycaemia can be severe when peptide metabolic agents are combined with insulin.
- Discontinue and seek urgent care for severe allergy or persistent vomiting.
- Keep out of reach of children.
Share on -
. Developed by